PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Sleep Sci 2017; 10(01): 19-27
DOI: 10.5935/1984-0063.20170004
REVIEW ARTICLE

Current and Future Treatment Options for Narcolepsy: A Review

Jackie Bhattarai
1   University of Kansas.
2   Dwight D. Eisenhower V.A. Medical Center.
,
Scott Sumerall
2   Dwight D. Eisenhower V.A. Medical Center.
3   University of Missouri-Kansas City.
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

Narcolepsy is a chronic neurological sleep disorder with potentially disabling symptoms ranging from occupational concerns to mental health difficulties. Recent advances related to the neurobiological basis of narcolepsy have led to newer pharmacological treatment options and adjunctive behavioral techniques that support symptom management. This article outlines evidence-based pharmacologic therapies, behavioral techniques, and psychosocial costs related to narcolepsy. Psychosocial factors, although frequently acknowledged, deserve further attention and awareness from researchers and providers. The American Academy of Sleep Medicine's (AASM) Quality Measure Drivers and potential future treatment options are also discussed.

Narcolepsy - Therapeutics - Pharmacologic actions - Behavioral medicine - Psychosocial impact


Publikationsverlauf

Eingereicht: 07. Juni 2016

Angenommen: 04. Januar 2017

Artikel online veröffentlicht:
29. September 2023

© 2023. Brazilian Sleep Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • REFERENCES

  • 1 Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med. 2014;15(5):502-7. doi: 10.1016/j.sleep.2014.01.015. PMID: 24780133.
  • 2 Black J, Reaven NL, Funk SE, McGaughey K, Ohayon M, Guilleminault C, et al. The Burden of Narcolepsy Disease (BOND) study: Health-care utilization and cost findings. Sleep Med. 2014;15(5):522-9. doi: 10.1016/j.sleep.2014.02.001. PMID: 24768358.
  • 3 Overeem S, Reading P, Bassetti CL. Narcolepsy. Sleep Med Clin. 2012;7(2):263-81. doi: 10.1016/j.jsmc.2012.03.013.
  • 4 Peacock J, Benca RM. Narcolepsy: clinical features, co-morbidities & treatment. Indian J Med Res. 2010;131:338-49. PMID: 20308759.
  • 5 American Academy of Sleep Medicine (AASM). The International Classification of Sleep Disorders - Third Edition (ICSD-3). Darien: American Academy of Sleep Medicine; 2014.
  • 6 Khan Z, Trotti LM. Central Disorders of Hypersomnolence: Focus on the Narcolepsies and Idiopathic Hypersomnia. Chest. 2015;148(1):262-73. doi: 10.1378/chest.14-1304.
  • 7 National Institute of Neurological Disorders and Stroke (NINDS). Narcolepsy fact sheet. Bethesda: National Institutes of Health; 2015.
  • 8 Jennum P, Ibsen R, Petersen ER, Knudsen S, Kjellberg J. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med. 2012;13(8):1086-93. doi: 10.1016/j.sleep.2012.06.006. PMID: 22841027.
  • 9 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington: American Psychiatric Association; 2013.
  • 10 Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med. 2010;31(2):371-81. doi: 10.1016/j.ccm.2010.02.014. PMID: 20488294.
  • 11 Liblau RS, Vassalli A, Seifinejad A, Tafti M. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol. 2015;14(3):318-28. doi: 10.1016/S1474-4422(14)70218-2. PMID: 25728441.
  • 12 Picchioni D, Hope CR, Harsh JR. A case-control study of the environmental risk factors for narcolepsy. Neuroepidemiology. 2007;29(3-4):185-92. doi: 10.1159/000111581. PMID: 18043003.
  • 13 Morrison I, Riha RL. Excessive daytime sleepiness and narcolepsy--an approach to investigation and management. Eur J Intern Med. 2012;23(2):110-7. doi: 10.1016/j.ejim.2011.09.005. PMID: 22284238.
  • 14 Baumann CR, Mignot E, Lammers GJ, Overeem S, Arnulf I, Rye D, et al. Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep. 2014;37(6):1035-42. doi: 10.5665/sleep.3756. PMID: 24882898; PMCID: PMC4015377.
  • 15 Carter LP, Acebo C, Kim A. Patients’ journeys to a narcolepsy diagnosis: a physician survey and retrospective chart review. Postgrad Med. 2014;126(3):216-24. doi: 10.3810/pgm.2014.05.2769. PMID: 24918805.
  • 16 Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16(1):9-18. doi: 10.1016/j.sleep.2014.10.002. PMID: 25458251.
  • 17 Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep. 2015;7:51-61. doi: 10.2147/NSS.S56077. PMID: 26045680; PMCID: PMC4447169.
  • 18 Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatr Dis Treat. 2008;4(3):557-66. PMID: 18830438; PMCID: PMC2526380.
  • 19 Walters AS, Silvestri R, Zucconi M, Chandrashekariah R, Konofal E. Review of the possible relationship and hypothetical links between attention deficit hyperactivity disorder (ADHD) and the simple sleep related movement disorders, parasomnias, hypersomnias, and circadian rhythm disorders. J Clin Sleep Med. 2008;4(6):591-600. PMID: 19110891; PMCID: PMC2603539.
  • 20 Roth T, Dauvilliers Y, Mignot E, Montplaisir J, Paul J, Swick T, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013;9(9):955-65. doi: 10.5664/jcsm.3004. PMID: 23997709; PMCID: PMC3746724.
  • 21 Krahn LE, Hershner S, Loeding LD, Maski KP, Rifkin DI, Selim B, et al. Quality measures for the care of patients with narcolepsy. J Clin Sleep Med. 2015;11(3):335. doi: 10.5664/jcsm.4554. PMID: 25700880; PMCID: PMC4346654.
  • 22 Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, et al.; Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705-11. PMID: 18246980; PMCID: PMC2276123.
  • 23 Black SW, Yamanaka A, Kilduff TS. Challenges in the Development of Therapeutics for Narcolepsy. Prog Neurobiol. 2015. pii: S0301-0082(15)30023-X. doi: 10.1016/j.pneurobio.2015.12.002. PMID: 26721620.
  • 24 Xie X, Smart TG. Gamma-hydroxybutyrate hyperpolarizes hippocampal neurones by activating GABAB receptors. Eur J Pharmacol. 1992;212(2-3):291-4. doi: 10.1016/0014-2999(92)90347-7. PMID: 1318216.
  • 25 Jara CO, Popp R, Zulley J, Hajak G, Geisler P. Determinants of depressive symptoms in narcoleptic patients with and without cataplexy. J Nerv Ment Dis. 2011;199(5):329-34. doi: 10.1097/NMD.0b013e3182174fd3. PMID: 21543952.
  • 26 Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med. 2013;14(6):488-92. doi: 10.1016/j.sleep.2013.03.002. PMID: 23643648.
  • 27 Nevsimalova S, Buskova J, Kemlink D, Sonka K, Skibova J. Does age at the onset of narcolepsy influence the course and severity of the disease? Sleep Med. 2009;10(9):967-72. doi: 10.1016/j.sleep.2009.01.010. PMID: 19423388.
  • 28 Marti I, Valko PO, Khatami R, Bassetti CL, Baumann CR. Multiple sleep latency measures in narcolepsy and behaviourally induced insufficient sleep syndrome. Sleep Med. 2009;10(10):1146-50. doi: 10.1016/j.sleep.2009.03.008. PMID: 19464232.
  • 29 Stores G. Errors in the recognition and diagnosis of sleep disorders. Prog Neurol Psychiatry. 2009;13(6):24-33. doi: 10.1002/pnp.146.
  • 30 Quinnell TG, Smith IE. Narcolepsy, idiopathic hypersomnolence and related conditions. Clin Med. 2011;11(3):282-6. PMID: 21902087.
  • 31 Fronczek R, Raymann RJ, Overeem S, Romeijn N, van Dijk JG, Lammers GJ, et al. Manipulation of skin temperature improves nocturnal sleep in narcolepsy. J Neurol Neurosurg Psychiatry. 2008;79(12):1354-7. doi: 10.1136/jnnp.2008.143610. PMID: 18653548.
  • 32 Sadeh A. The role and validity of actigraphy in sleep medicine: an update. Sleep Med Rev. 2011;15(4):259-67. doi: 10.1016/j.smrv.2010.10.001. PMID: 21237680.
  • 33 Fronczek R, Raymann RJ, Romeijn N, Overeem S, Fischer M, van Dijk JG, et al. Manipulation of core body and skin temperature improves vigilance and maintenance of wakefulness in narcolepsy. Sleep. 2008;31(2):233-40. PMID: 18274271; PMCID: PMC2225580.
  • 34 Peters A, Cunnington D, Greenwood KM. The need for psychological therapies for sleep disorders other than insomnia: Potential for mindfulness. Health Psychol Rev. 2016;18(2):73-9.
  • 35 Marín Agudelo HA, Jiménez Correa U, Carlos Sierra J, Pandi-Perumal SR, Schenck CH. Cognitive behavioral treatment for narcolepsy: Can it complement pharmacotherapy? Sleep Sci. 2014;7:30-42. doi: 10.1016/j.slsci.2014.07.023; PMID: 26483898; PMCID: PMC4521653.
  • 36 Vignatelli L, Plazzi G, Peschechera F, Delaj L, D’Alessandro R. A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. Sleep Med. 2011;12(1):19-23. doi: 10.1016/j.sleep.2010.07.008. PMID: 20851047.
  • 37 Rosenberg R, Kim AY. The AWAKEN survey: knowledge of narcolepsy among physicians and the general population. Postgrad Med. 2014;126(1):78-86. doi: 10.3810/pgm.2014.01.2727. PMID: 24393754.
  • 38 Jennum P, Ibsen R, Knudsen S, Kjellberg J. Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study. Sleep. 2013;36(6):835-40. doi: 10.5665/sleep.2706. PMID: 23729926; PMCID: PMC3649826.
  • 39 Jennum P, Knudsen S, Kjellberg J. The economic consequences of narcolepsy. J Clin Sleep Med. 2009;5(3):240-5. PMID: 19960645; PMCID: PMC2699169.
  • 40 Black SW, Morairty SR, Chen TM, Leung AK, Wisor JP, Yamanaka A, et al. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy. J Neurosci. 2014;34(19):6485-94. doi: 10.1523/JNEUROSCI.0080-14.2014. PMID: 24806675; PMCID: PMC4012308.
  • 41 Miyagawa T, Kawashima M, Nishida N, Ohashi J, Kimura R, Fujimoto A, et al. Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet. 2008;40(11):1324-8. doi: 10.1038/ng.231. PMID: 18820697.
  • 42 Miyagawa T, Miyadera H, Tanaka S, Kawashima M, Shimada M, Honda Y, et al. Abnormally low serum acylcarnitine levels in narcolepsy patients. Sleep. 2011;34(3):349-53A. PMID: 21358852; PMCID: PMC3041711.
  • 43 Miyagawa T, Kawamura H, Obuchi M, Ikesaki A, Ozaki A, Tokunaga K, et al. Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. PLoS One. 2013;8(1):e53707. doi: 10.1371/journal.pone.0053707; PMID: 23349733; PMCID: PMC3547955.
  • 44 Black SW, Schwartz MD, Chen TM, Hoener MC, Kilduff TS. Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics. Biol Psychiatry. 2016. pii: S0006-3223(16)32921-3. doi: 10.1016/j.biopsych.2016.10.012. PMID: 27919403.
  • 45 Mahlios J, De la Herrán-Arita AK, Mignot E. The autoimmune basis of narcolepsy. Curr Opin Neurobiol. 2013;23(5):767-73. doi: 10.1016/j.conb.2013.04.013. PMID: 23725858; PMCID: PMC3848424.
  • 46 Mignot E, Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep. 2005;28(6):754-63. PMID: 16477963.
  • 47 Cochen De Cock V, Dauvilliers Y. Current and future therapeutic approaches in narcolepsy. Future Neurol. 2011;6(6):771-82.
  • 48 Nishino S, Arrigoni J, Shelton J, Kanbayashi T, Dement WC, Mignot E. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci. 1997;17(16):6401-8. PMID: 9236248.